Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Looking at Coloplast A/S's (CPH:COLO B) earnings update in March 2019, analysts seem cautiously bearish, with earnings expected to grow by 12% in the upcoming year against the higher past 5-year average growth rate of 16%. By 2020, we can expect Coloplast’s bottom line to reach ø4.3b, a jump from the current trailing-twelve-month of ø3.8b. Below is a brief commentary around Coloplast's earnings outlook going forward, which may give you a sense of market sentiment for the company. Investors wanting to learn more about other aspects of the company should research its fundamentals here.
Exciting times ahead?
The longer term view from the 16 analysts covering COLO B is one of positive sentiment. Broker analysts tend to forecast up to three years ahead due to a lack of clarity around the business trajectory beyond this. To get an idea of the overall earnings growth trend for COLO B, I’ve plotted out each year’s earnings expectations and inserted a line of best fit to determine an annual rate of growth from the slope of this line.
From the current net income level of ø3.8b and the final forecast of ø5.4b by 2022, the annual rate of growth for COLO B’s earnings is 10%. EPS reaches DKK26.12 in the final year of forecast compared to the current DKK18.12 EPS today. With a current profit margin of 23%, this movement will result in a margin of 26% by 2022.
Future outlook is only one aspect when you're building an investment case for a stock. For Coloplast, I've put together three relevant aspects you should look at:
- Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Valuation: What is Coloplast worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether Coloplast is currently mispriced by the market.
- Other High-Growth Alternatives : Are there other high-growth stocks you could be holding instead of Coloplast? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.